CA3234634A1 - Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells - Google Patents
Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells Download PDFInfo
- Publication number
- CA3234634A1 CA3234634A1 CA3234634A CA3234634A CA3234634A1 CA 3234634 A1 CA3234634 A1 CA 3234634A1 CA 3234634 A CA3234634 A CA 3234634A CA 3234634 A CA3234634 A CA 3234634A CA 3234634 A1 CA3234634 A1 CA 3234634A1
- Authority
- CA
- Canada
- Prior art keywords
- insdseq
- insdqualifier
- adult
- cell
- insdfeature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257827P | 2021-10-20 | 2021-10-20 | |
| US63/257,827 | 2021-10-20 | ||
| US202263350039P | 2022-06-08 | 2022-06-08 | |
| US202263350041P | 2022-06-08 | 2022-06-08 | |
| US202263350042P | 2022-06-08 | 2022-06-08 | |
| US63/350,042 | 2022-06-08 | ||
| US63/350,041 | 2022-06-08 | ||
| US63/350,039 | 2022-06-08 | ||
| PCT/US2022/047083 WO2023069482A1 (en) | 2021-10-20 | 2022-10-19 | Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3234634A1 true CA3234634A1 (en) | 2023-04-27 |
Family
ID=84359179
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3234634A Pending CA3234634A1 (en) | 2021-10-20 | 2022-10-19 | Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells |
| CA3235250A Pending CA3235250A1 (en) | 2021-10-20 | 2022-10-19 | Methods and compositions for rejuvenating cns glial populations by suppression of transcription factors |
| CA3235458A Pending CA3235458A1 (en) | 2021-10-20 | 2022-10-19 | Microrna-mediated methods for rejuvenating cns glial populations |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235250A Pending CA3235250A1 (en) | 2021-10-20 | 2022-10-19 | Methods and compositions for rejuvenating cns glial populations by suppression of transcription factors |
| CA3235458A Pending CA3235458A1 (en) | 2021-10-20 | 2022-10-19 | Microrna-mediated methods for rejuvenating cns glial populations |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20230190961A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4419679A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024539080A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022369984A1 (cg-RX-API-DMAC7.html) |
| CA (3) | CA3234634A1 (cg-RX-API-DMAC7.html) |
| WO (3) | WO2023069484A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230190961A1 (en) | 2021-10-20 | 2023-06-22 | University Of Rochester | Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells |
| IL319917A (en) * | 2022-10-19 | 2025-05-01 | Univ Rochester | Methods and compositions for renewing glial populations of the central nervous system with expression of the transcription factor BCL11A |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US275794A (en) | 1883-04-10 | Eugene ward | ||
| US748529A (en) | 1903-09-03 | 1903-12-29 | Troy Laundry Machinery Co Ltd | Marking-machine. |
| US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| DE69942334D1 (de) | 1998-03-02 | 2010-06-17 | Massachusetts Inst Technology | Poly-zinkfinger-proteine mit verbesserten linkern |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| US20030223972A1 (en) | 2002-02-15 | 2003-12-04 | Goldman Steven A. | Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells |
| US20040029269A1 (en) | 2002-05-07 | 2004-02-12 | Goldman Steven A | Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells |
| US7485291B2 (en) | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| CA2580515C (en) | 2004-10-04 | 2017-05-02 | National Research Council Of Canada | Expression system, components thereof and methods of use |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| US20150362508A1 (en) | 2013-01-30 | 2015-12-17 | Benaroya Research Institute At Virginia Mason | Effector t cell rsistance |
| US12522594B2 (en) | 2017-02-09 | 2026-01-13 | Deutsches Krebsforschungszentrum | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
| US12303549B2 (en) | 2018-06-21 | 2025-05-20 | University Of Rochester | Methods of treating or inhibiting onset of Huntington's disease |
| AU2019342741B2 (en) * | 2018-09-19 | 2025-12-11 | Lineage Cell Therapeutics, Inc. | Methods for differentiating pluripotent stem cells in dynamic suspension culture |
| EP3923962A2 (en) * | 2019-02-13 | 2021-12-22 | University of Rochester | Gene networks that mediate remyelination of the human brain |
| EP4099993A4 (en) | 2020-02-06 | 2024-03-13 | Emerald Health Pharmaceuticals Inc. | COMPOSITION AND METHOD FOR TREATING AND PREVENTING CARDIAC, LUNG, SKIN AND KIDNEY FIBROSIS |
| IL311610A (en) | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
| US20230241118A1 (en) | 2021-10-20 | 2023-08-03 | University Of Rochester | Rejuvenation treatment of age-related white matter loss |
| US20230190961A1 (en) | 2021-10-20 | 2023-06-22 | University Of Rochester | Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells |
-
2022
- 2022-10-19 US US18/047,744 patent/US20230190961A1/en active Pending
- 2022-10-19 EP EP22803427.8A patent/EP4419679A1/en active Pending
- 2022-10-19 JP JP2024523274A patent/JP2024539080A/ja active Pending
- 2022-10-19 CA CA3234634A patent/CA3234634A1/en active Pending
- 2022-10-19 AU AU2022369984A patent/AU2022369984A1/en active Pending
- 2022-10-19 AU AU2022370552A patent/AU2022370552A1/en active Pending
- 2022-10-19 US US17/968,984 patent/US12565648B2/en active Active
- 2022-10-19 WO PCT/US2022/047085 patent/WO2023069484A1/en not_active Ceased
- 2022-10-19 CA CA3235250A patent/CA3235250A1/en active Pending
- 2022-10-19 US US18/047,749 patent/US12686868B2/en active Active
- 2022-10-19 WO PCT/US2022/047083 patent/WO2023069482A1/en not_active Ceased
- 2022-10-19 CA CA3235458A patent/CA3235458A1/en active Pending
- 2022-10-19 WO PCT/US2022/047079 patent/WO2023069478A1/en not_active Ceased
- 2022-10-19 EP EP22823646.9A patent/EP4419685A1/en active Pending
- 2022-10-19 JP JP2024523275A patent/JP2024539081A/ja active Pending
-
2023
- 2023-09-14 US US18/467,442 patent/US20240167034A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023069482A1 (en) | 2023-04-27 |
| EP4419679A1 (en) | 2024-08-28 |
| WO2023069478A8 (en) | 2023-07-27 |
| US20230133695A1 (en) | 2023-05-04 |
| JP2024539080A (ja) | 2024-10-28 |
| US20230190961A1 (en) | 2023-06-22 |
| AU2022369984A1 (en) | 2024-03-28 |
| US20230212568A1 (en) | 2023-07-06 |
| EP4419685A1 (en) | 2024-08-28 |
| CA3235250A1 (en) | 2023-04-27 |
| JP2024539081A (ja) | 2024-10-28 |
| WO2023069478A9 (en) | 2023-08-24 |
| WO2023069484A1 (en) | 2023-04-27 |
| US20240167034A1 (en) | 2024-05-23 |
| US12565648B2 (en) | 2026-03-03 |
| CA3235458A1 (en) | 2023-04-27 |
| AU2022370552A1 (en) | 2024-03-28 |
| WO2023069478A1 (en) | 2023-04-27 |
| US12686868B2 (en) | 2026-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wibrand et al. | MicroRNA regulation of the synaptic plasticity-related gene Arc | |
| Ehrlich et al. | Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors | |
| Lulli et al. | MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A | |
| Zhang et al. | The Wnt effector TCF7l2 promotes oligodendroglial differentiation by repressing autocrine BMP4-mediated signaling | |
| US20230057355A1 (en) | Gene networks that mediate remyelination of the human brain | |
| US20240167034A1 (en) | Methods and compositions for rejuvenating cns glial populations by suppresion of transcription factors | |
| JP2024540972A (ja) | 加齢性白質喪失の若返り治療 | |
| Mariani et al. | Repression of developmental transcription factor networks triggers aging-associated gene expression in human glial progenitor cells | |
| Aigner et al. | Human pluripotent stem cell models of autism spectrum disorder: emerging frontiers, opportunities, and challenges towards neuronal networks in a dish | |
| WO2018007428A1 (en) | Means and methods for the generation of oligodendrocytes | |
| US20240165269A1 (en) | Methods and compositions for rejuvenating cns glial populations with bcl11a transcription factor expression | |
| Lin et al. | SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants | |
| Piatek et al. | MS CD49d+ CD154+ lymphocytes reprogram oligodendrocytes into immune reactive cells affecting CNS regeneration | |
| CN118318040A (zh) | 通过使神经胶质祖细胞恢复活力来治疗髓磷脂缺乏的组合物和方法 | |
| Zhao et al. | MiR-463-3p inhibits tibial nerve regeneration via post-transcriptional suppression of SPRR1A | |
| Mariani et al. | Age-Associated Induction of Senescent Transcriptional Programs in Human Glial Progenitor Cells | |
| Giagnorio | Revealing the involvement of MALAT1, NEAT1, HOTTIP lncRNAs in Amyotrophic Lateral Sclerosis (ALS) via an induced pluripotent stem cell (iPSC)-derived muscle cell model | |
| Song | Three-dimensional epigenomic characterization reveals insights into gene regulation and disease in the human brain | |
| Rochat et al. | Expression of a miRNA targeting mutated SOD1 in astrocytes induces motoneuron plasticity and improves neuromuscular function in ALS mice | |
| Goff | The Identification of Transcriptional Signatures of Steroid Response in Human Neurons and Microrna Networks as a Contributor to Reproductive Steroid Pathology | |
| Wapinski | Mechanistic Understanding of Cell Fate Decisions Towards Neuronal Lineage | |
| Clementina | Lack of Mecp2 interferes with cortical progenitors proliferation and differentiation. | |
| Dubinsky | Expression profiling and functional studies of non-coding RNAs in the central nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240913 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251010 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251010 |